Product Description
Betulinic acid is a natural product with a range of biological effects, for example potent antitumor activity. This anticancer property is linked to its ability to induce apoptotic cell death in cancer cells by triggering the mitochondrial pathway of apoptosis. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658785/)
Mechanisms of Action: TOP Inhibitor, SP1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Advanced Life Sciences
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dysplastic Nevus Syndrome
Phase 1: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ALS-357-001 | P1 |
Unknown status |
Melanoma |
2009-06-01 |
2019-03-18 |
Treatments |
|
| Moderate to Severe Dysplasia | P2 |
Withdrawn |
Dysplastic Nevus Syndrome |
2015-12-01 |
2021-06-29 |
Patient Enrollment|Primary Endpoints |